Published 2023 | Version v1
Poster Open

DRUG REPURPOSING AGAINST DIFFERENTIALLY EXPRESSED CANDIDATES FROM OVARIAN CANCER TRANSCRIPTOMES

Authors/Creators

  • 1. Precision Medicine Lab (CECOS RMI)
  • 2. Bacha Khan Medical College, Mardan
  • 3. Institute of Integrative Biosciences, CECOS University
  • 4. Department of Bioengineering, University of Engineering and Applied Sciences, Swat, Pakistan
  • 5. Centre for Genomic Sciences, Rehman Medical Institute Peshawar, Pakistan

Description

Ovarian cancer is a significant contributor to cancer-related mortality among women worldwide. However, because ovarian cancer is often undiagnosed until late in the disease's progression, it is also the fifth leading cancer-related cause of death among women in the US¹. Metastasis remains a major challenge, as it often leads to more aggressive disease and poorer prognosis. Understanding the molecular changes that occur during the transition from primary to metastatic tumors is crucial for developing targeted therapies and improving patient outcomes.

Files

Muhibullah Ghafoorzai 2023.pdf

Files (3.8 MB)

Name Size Download all
md5:6c145f26f9092899b21cb7b3730827a3
3.8 MB Preview Download

Additional details

References

  • 1. September is Ovarian Cancer Awareness Month (2023), American Association for Cancer Research (AACR).
  • 2. allinen, H., et al. "Comparative transcriptome analysis of matched primary and distant metastatic ovarian carcinoma," BMC Cancer, 2019 Nov 19; 19(1): 1121. PMID: 31744494.
  • 3. Mitra, S., et al. "Transcriptome Profiling Reveals Matrisome Alteration as a Key Feature of Ovarian Cancer Progression," Cancers (Basel), 2019 Oct 9; 11(10). PMID: 31600962.
  • 4. Brodsky, A. S., et al. "Expression profiling of primary and metastatic ovarian tumors reveals differences indicative of aggressive disease," PLoS One, 2014; 9(4): e94476. PMID: 24732363.
  • 5. Kotnik, T., et al. "Genetic characterization of primary and metastatic high-grade serous ovarian cancer tumors reveals distinct features associated with survival," Communications Biology, 2023; 6(1): 688.
  • 6. Hu, Y., et al. "Are Epithelial Ovarian Cancers of the Mesenchymal Subtype Actually Intraperitoneal Metastases to the Ovary?" Front Cell Dev Biol, 2020; 8: 647. PMID: 32766252.